Tag - Akston Biosciences

Akston Biosciences’ AKS-107 Study Published in Frontiers in Immunology, Displaying Ambifect® Platform’s Versatility

Antonette Ho2024-03-23T17:42:29-04:00Akston Biosciences, dedicated to accelerating the next revolution in Animal Health, announced the publication in Frontiers in Immunology of a study on AKS-107, an innovative antigen-specific immunotherapy based on Akston's Ambifect® Fc-fusion protein platform. The study demonstrated AKS-107's potential to target and delete insulin-specific B cells, which are implicated in the development of Type 1 Diabetes (T1D). Fc-fusion proteins based on this platform can be designed to interact only with parts of the immune system related to the target disease...

Akston Biosciences’ AKS-452 Vaccine Study Published in Nature, Showcasing Ambifect® Platform’s Versatility

Antonette Ho2024-02-27T23:27:09-05:00Akston Biosciences, dedicated to accelerating the next revolution in Animal Health, announced the publication in Nature Vaccines of phase II study results for AKS-452, based on Akston’s Ambifect® Fc-fusion protein platform. This Netherlands study showed the ability of a 90 ug subcutaneous dose to safely boost the immune response of individuals previously primed with a registered mRNA- or adenovirus-based SARS-CoV-2 vaccine. Fc-fusion protein vaccines derived from Akston’s platform provide a unique set of benefits, including inherent stability at ambient temperatures...

Akston Biosciences wins Innovation Award at Animal Health Summit

Antonette Ho2023-09-12T00:00:41-04:00Akston Biosciences Corp, a Massachusetts-based startup focused on developing long-acting protein therapeutics for pets, has received the Innovation Award at the the 2023 Animal Health Summit hosted by KC Animal Health Corridor at the Midland Theatre in Kansas City, Missouri. This is the highest distinction a company can achieve at the event. During the Emerging Companies part of the summit which consisted of a “Shark Tank-style” presentation, Akston Biosciences was among 13 animal health startups to describe their visions for...

Akston Biosciences to Focus on Strong Animal Health Pipeline

Antonette Ho2023-08-23T00:51:46-04:00Akston Biosciences Corporation announced today that it will focus on inventing, developing, and manufacturing breakthrough protein therapeutics for Companion Animal Health, utilizing its versatile Ambifect™ Fc-fusion platform and its Beverly, Massachusetts cGMP biologics manufacturing facility. Akston is spinning off its infectious disease vaccine and human Type 1 Diabetes prevention lines of business into two wholly-owned subsidiaries: Vakston, Inc. and Diamune Therapeutics, Inc. Akston’s most advanced Animal Health candidates, AKS-321d and AKS-425c, are once-a-week insulins designed to treat canine and feline...

Akston Biosciences Ends Vaccine Partnership with Stelis, Continues to Advance COVID Universal Booster EUA

Antonette Ho2023-03-24T16:00:03-04:00Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today it has ended its AKS-452 licensing, manufacturing, and commercialization agreement with Stelis Biopharma Limited, an arm of Strides Pharma Science Ltd. Akston has reclaimed all rights to AKS-452, a room temperature stable, low-cost, protein subunit COVID-19 vaccine. AKS-452 has completed a Phase II/III clinical trial in India, with data showing robust safety profile and a 91% seroconversion rate at Day 56. Akston is now working with a...

Akston Biosciences Strengthens Board with Addition of John T. Preston

Antonette Ho2023-02-14T19:50:18-05:00Akston Biosciences Corporation, a clinical-stage biotechnology company, today announced that John T. Preston, a founder of TEM Capital, has joined its Board of Directors. A recipient of numerous awards and previous advisor to several government agencies and expert witness for Congress, Preston brings to Akston his decades of experience in technology commercialization and intellectual property licensing. Preston spent most of his career at the Massachusetts Institute of Technology (MIT), managing the interface between researchers and industry. His titles included Associate...

Akston Biosciences Announces Positive Interim Phase II Results from COVID “Universal” Booster Vaccine Trial

Ziad2022-11-25T13:59:44-05:00Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, today announced top-line clinical results for its Phase II COVID-19 “universal” booster vaccine, AKS-452. An interim analysis of the data found that 93% of subjects previously vaccinated with Pfizer, Moderna, Johnson & Johnson (Janssen), and AstraZeneca vaccines showed an increase in neutralizing antibody titers after receiving a single dose of AKS-452. The average neutralization titers across all subjects increased 4-fold against the Wuhan strain and 5-fold against the Omicron...

Akston starts small and likes it that way

Ziad2022-11-25T13:59:44-05:00Akston Biosciences Corp. emerged from a successful small company that was sold to a pharma major. For Todd Zion, that’s a back-to-basics move that suits him just fine. Zion co-founded Smartcells Inc. in 2003 with technology developed at the Massachusetts Institute of Technology. The company went on to develop the once-daily injectable self-regulating insulin product, Smartinsulin, and sold it to Merck & Co. in what was at the time one of the largest preclinical pharmaceutical acquisitions ever. Read more >>

Strides Pharma jumps on positive outcome of COVID-19 vaccine trials

Ziad2022-11-25T13:59:45-05:00Strides Pharma Science rallied 7.70% to Rs 336.50 after the company's subsidiary Biolexis and Akston Biosciences announce encouraging top-line results from phase II/III trial of their thermostable 2nd gen COVID-19 vaccine. The vaccine was well tolerated, with no reported safety issues and is shelf-stable for over six months at room temperature at 25 celsius and potency for one month at 37 celsius. The interim analysis showed 91% seroconversion rate at day 56. The vaccine will be produced at Stelis Biopharma,...

Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine

Ziad2022-11-25T13:59:45-05:00Akston Biosciences Corporation and Biolexis, a Strides Group Company, today announced results from a Phase II/III clinical trial in India of the SARS-CoV-2 vaccine, AKS-452, in which 1,600 healthy volunteers participated – 100 in an open-label bridging study and 1,500 in Phase II/III, double-blind, placebo-controlled trial. An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56. Volunteers in the bridging study had antibody titers that persisted at statistically-significant high levels through...